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Monozygotic twins discordant for common
variable immunodeficiency reveal impaired DNA
demethylation during naı̈ve-to-memory B-cell
transition
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Common variable immunodeficiency (CVID), the most frequent primary immunodeficiency
characterized by loss of B-cell function, depends partly on genetic defects, and epigenetic
changes are thought to contribute to its aetiology. Here we perform a high-throughput DNA
methylation analysis of this disorder using a pair of CVID-discordant MZ twins and show
predominant gain of DNA methylation in CVID B cells with respect to those from the healthy
sibling in critical B lymphocyte genes, such as PIK3CD, BCL2L1, RPS6KB2, TCF3 and KCNN4.
Individual analysis confirms hypermethylation of these genes. Analysis in naive, unswitched
and switched memory B cells in a CVID patient cohort shows impaired ability to demethylate
and upregulate these genes in transitioning from naive to memory cells in CVID. Our results
not only indicate a role for epigenetic alterations in CVID but also identify relevant
DNA methylation changes in B cells that could explain the clinical manifestations of CVID
individuals.
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C
ommon variable immunodeficiency (CVID) is the most
frequent symptomatic primary immunodeficiency (PID)
in adults. It comprises a heterogeneous group of disorders
that are characterized by hypogammaglobulinaemia that predis-
poses CVID individuals to recurrent bacterial infections that
mainly affect the respiratory and gastrointestinal tracts1. CVID
patients present a marked decrease in IgG and at least one of the
isotypes IgM or IgA. Other criteria used for diagnosis include the
onset of immunodeficiency after the age of 2 years, a poor specific
antibody response and exclusion of known monogenic causes
of hypogammaglobulinaemia2. The clinical manifestations of
CVID are highly variable. Several complications, such as
lymphoproliferative disorders and inflammatory diseases, occur
in some CVID patients. In addition, over 25% of CVID cases
present autoimmune manifestations. These complications are
poorly understood and sometimes associated with poor
prognosis3.
CVID is usually detected sporadically in patients with no
family history of immunodeficiency. However, for B10% of
subjects other first-degree relatives may be either hypogamma-
globulinaemic or present selective IgA deficiency4,5. In fact,
progression from selective IgA deficiency to CVID has been
observed in several patients. Although CVID is considered to be
an intrinsic defect, it can be clinically developed at any age
suggesting cumulative deterioration of B-cell functions in a
putative multifactorial pathogenic process. In this sense,
comparing genetically identical monozygotic (MZ) twins
concordant or discordant for CVID could be a useful strategy
for dissecting the genetic and non-genetic components of this
disease. Enormous efforts are made to find genetic defects that
would help understand CVID aetiology and predict the clinical
outcome. However, genetic alterations account for the condition
in only B10–20% of immunodeficiency patients, and the
majority lack a definite molecular genetic diagnosis6. Genetic
mutations can affect several immune processes, especially those
related to B-cell activation, T-cell signalling and cytokine
expression6. For instance, there are mutations in the genes
encoding CD19, CD21, CD81, PLC-g2, which are proteins
involved in signalling through the B-cell receptor (BCR), and in
those encoding ICOS, BAFFR, TACI, MSH5, involved in co-
stimulatory pathways necessary for isotype switching and
somatic hypermutation during B-cell activation7. Analysis of
consanguineous families affected by hypogammaglobulinaemia
has led to identifying new mutations in genes such as LRBA8. In
addition, mutations that cause loss and gain of function have
been identified in genes such as CTLA4 (ref. 9) and PIK3CD10,
respectively.
CVID is characterized by deregulation of various immune cell
types. Examples include reduction of CD4 T cells and increase in
CD8 T cells11, and reductions in both myeloid and plasmacytoid
dendritic cell frequencies12. However, the most uniform
alteration is observed in the B-cell compartment. Specifically,
CVID patients display a severe deficiency of switched memory B
cells CD27þ IgD IgM (ref. 13) and, in fact, it has been
proposed to subclassify patients based on the distribution of
naive/memory B cells defined by the expression of IgD and CD27
(ref. 14). Moreover, the expansion of certain B-cell subsets, such
as CD21lo or transitional B cells, correlates with complications
such as splenomegaly and lymphadenopathy, respectively, while
the reduction of class-switched memory B cells has been linked
with granulomatous disease and autoimmune cytopenias15.
During B-cell differentiation, identity is acquired through
significant changes in gene expression. These changes are tightly
regulated, not only by successive networks of transcription
factors but also by epigenetic mechanisms, including DNA
methylation16,17. DNA methylation plays a fundamental role in
differentiation by driving and stabilizing gene activity states
during cell fate decisions. Methylation takes place in cytosines
located in CpG dinucleotides. CpGs in different regions play a
regulatory role, including those in CpG islands, which are
CpG-dense regions, ‘shores’, located 1–2 kb upstream or
downstream of CpG islands, and ‘shelves’, adjacent to
shores18,19. Promoters and enhancers are common hotspots for
functionally relevant DNA methylation changes. Thus, DNA
methylation is important in processes such as the maintenance of
chromosome stability, genomic imprinting and regulation of gene
expression20. In fact, a DNA demethylation signature has been
described in both early stages of B-cell development21 and late
stages, during activation of naive B cells22. In addition, profiling
of the DNA methylome and transcriptome of B lymphocyte
subsets representing stages of the humoral response before and
after antigen exposure in vivo reveals the generation of DNA
methylation profiles that map to transcription-binding sites and
that are retained in the progeny of activated B cells, generating a
similar epigenetic signature in downstream memory cells and
plasma cells, with distinct transcriptional programmes22.
Direct comparison of the DNA methylation patterns in cells
from identical twins is an excellent experimental approach for
testing the contribution of epigenetic changes to complex diseases
because DNA sequence differences, including single-nucleotide
polymorphisms, do not interfere with such an analysis. Recent
studies with twins in the context of immune-related disease23–25
have demonstrated the existence of genome-wide epigenetic
differences that could explain differences in phenotype. Given the
importance of B cells in CVID aetiology and the influence of
DNA methylation on the normal function and development of
this cell type, in the work reported here, we initially compared the
DNA methylation profiles of B cells of a single MZ twin pair
discordant for CVID. The comparison revealed significant
changes in DNA methylation associated with CVID, specifically
the hypermethylation of several genes of relevance in B-cell
biology, including PIK3CD, BCL2L1, RPS6KB2, TCF3 and
KCNN4. The comparison of the DNA methylation status of
selected genes from the above screening in naive, unswitched and
switched memory B cells from a cohort of healthy versus CVID
individuals revealed that the aforementioned hypermethylation
does not affect the naive cell subpopulation. However, we
observed that CVID individuals were impaired for the
demethylation and upregulation of these genes in the transition
from naive to unswitched and switched memory cells. Our results
reveal a novel mechanism by which the acquisition of the
epigenetic signature in memory cells in CVID individuals is
impaired, perhaps accounting for their decreased survival in
CVID patients, and suggesting potential targets for clinical
intervention.
Results
CVID-discordant twins reveal DNA methylation changes. To
investigate the potential occurrence of DNA methylation altera-
tions in B cells of CVID individuals, we first performed DNA
methylation screening on CD19þ cells isolated from a pair of
MZ twins discordant for CVID. One of the individuals had been
diagnosed with archetypical CVID, with a virtual absence of
switched memory B cells, whereas his healthy sibling only pre-
sented moderately reduced levels of IgA, with IgG that had been
increasing to normal levels with age. For the analysis, we used
bead arrays to interrogate the DNA methylation status of
4450,000 CpG sites across the entire genome covering 99% of
RefSeq genes. Samples were processed and analysed in triplicate.
We observed that array-wide technical variability (three replicates
per twin: variability within a twin) and biological variability
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(differences between twins) were similar. For this reason we
designed a robust CpG criterion selection (see Bioinformatics
analysis in Methods) in order to identify differentially methylated
candidate regions that were profiled later replication in an
independent replication cohort. By the selection procedure we
identified 311 CpG sites that were differentially DNA-methylated
between the CVID individual and his healthy matching twin
(Supplementary Data 1). Given the small range of changes, we
considered a CpG to be differentially methylated when the dif-
ference in b was greater than 10%. Approximately 75% of these
differentially methylated CpGs (230 out of 311) displayed higher
methylation levels in the CVID individual than in his sibling, and
the remaining 25% (81 CpGs) were less methylated in the CVID
compared with the healthy sibling (Fig. 1a). The majority of these
changes occurred in annotated genes (79.1% and 80.2% in the
hypermethylated and hypomethylated sets, respectively; Fig. 1b).
Of the gene-associated hypermethylated CpGs, 131 were located
in gene bodies, 28 at the 30 untranslated region (UTR) and 54 at
gene promoters. In the hypomethylated set of CpGs, 26 CpGs
were located in gene bodies, 17 CpGs at 30 UTR and 37 in
promoter regions (Fig. 1b).
We then performed gene ontology (GO) analysis to determine
whether the differentially methylated genes were associated with
potentially relevant biological processes in CVID. We indepen-
dently analysed the lists of hypermethylated and hypomethylated
genes. In the hypermethylated set of genes, there was enrichment
of important GO categories such as immune system process
(GO:0002376), intracellular signal transduction (GO:0035556),
defense response (GO:0006952), positive regulation of macro-
molecule biosynthetic process (GO:0010557) and positive
regulation of cellular metabolic process (GO:0031325). We found
12–19% of the hypermethylated genes to be associated with these
categories. A smaller percentage of hypermethylated genes was
associated with other interesting categories in CVID such as
regulation of lymphocyte chemotaxis (GO:1901623), or positive
regulation of T-cell chemotaxis (GO:0010820). In the hypo-
methylated group, the functional categories were less obviously
relevant in the context of B-cell biology. We found that 24% of
genes were associated with cell adhesion (GO:0007155), 20% were
in the cell–cell adhesion (GO:0098609) and homophilic cell
adhesion (GO:0007156) categories. Around 3–5% of hypo-
methylated genes were associated with other categories, such as
response to cAMP (GO:0051591), cell fate specification involved
in pattern specification (GO:0060573) and cell fate specification
(GO:0001708; Fig. 1c).
The hypermethylated genes (Table 1) were particularly
interesting for their relevance in BCR signalling pathways such
as: PI3K signalling in B lymphocytes, FcRIIB signalling in B
lymphocytes, CD27 signalling, P38MAPK, CD40 signalling,
NF-KB signalling, APRIL-mediated signalling, B-cell-activating
factor signalling, pathway of inositol phosphate compounds.
All these genes have associated network functions that the
programme identified as: cell death and survival, cell-mediated
immune response and cellular movement.
In addition to the overall analysis of functional categories,
inspection of individual genes made it possible to identify those
essential for B-cell biology and function from among the list of
hypermethylated genes. These included genes such as PIK3CD,
TCF3, KCNN4, BCL2L1 and RPS6KB2, among others (Table 1).
PIK3CD encodes the catalytic subunit delta of the phosphatidy-
linositol-4,5-bisphosphate 3-kinase, a molecule that regulates
natural antibody production, marginal zone and B-1 B-cell
function, and autoantibody responses26. Another interesting
example is KCNN4, a molecule that is activated during B-cell
activation and helps maintain elevated Ca2þ levels during signal
transduction27. BCL2L1 encodes an apoptotic inhibitor that plays
a critical role in the germinal centre28. The list of hypomethylated
genes had less obvious candidates in terms of B-cell biology.
We then compared the DNA methylation data with existing
gene expression data obtained from B cells of CVID patients
versus healthy donors (accession no. GSE17269)29 (Fig. 1d).
Despite the differences between this study focusing on a small
cohort and also using the naive CD19þ subset, we found a
significant number of genes with differences in expression among
those displaying differences in DNA methylation (Fig. 1d). This
suggests that the methylation changes occurring in CVID B cells
may affect the overall expression of the associated genes.
DNA methylation changes in CVID are B-cell-specific. To
confirm the results obtained from the DNA methylation arrays,
we performed bisulfite pyrosequencing of a selection of the
aforementioned genes (Table 1), hypermethylated in B cells iso-
lated from the same pair of twins discordant for CVID. In brief,
the selection of genes was carried out among those displaying the
largest changes in DNA methylation between the CVID and
healthy sibling, and also to cover different functions in B-cell
biology: PIK3CD, RPS6KB2 encode proteins involved in the cell
proliferation, cell growth and protein synthesis, that occur in
response to BCR signalling; BCL2L1 encodes a protein with anti-
apoptotic effects. TCF3 encodes a transcription factor essential in
the establishment of B-cell identity. PTPRCAP encodes a protein
necessary for proper phosphatase activity of CD45 during BCR
signalling, and CORO1B, KCNN4 and KCNC4 encode proteins
that are involved in Caþ 2 signalling. We focused on looking at
the same CpG sites for which significant changes had been
identified (Fig. 2a). Despite the modest differences in DNA
methylation measured by the initial high-throughput strategy, we
confirmed by bisulfite pyrosequencing a robust increase in DNA
methylation in the CVID sibling with respect to the healthy
sibling (Fig. 2b), with very similar values to those obtained using
bead arrays (Fig. 2c). We also tested the DNA methylation
changes in CD4þ cells (T lymphocytes) and CD14þ cells
(monocytes) from the same individuals (Fig. 2b). In contrast with
the robust increase in the frequency of B cells from the CVID
sibling with respect to the healthy sibling, we observed no
differences or changes in the opposite direction in T cells
and monocytes, highlighting the specificity of the observed
CVID-associated hypermethylation of these genes to B cells.
As mentioned earlier, CVID individuals have been reported to
contain fewer switched memory cells. Our results showing DNA
methylation differences between this CVID individual and his
matching healthy sibling using total CD19þ may simply reflect
changes in the proportion of different B-cell subsets between
these two individuals if the DNA methylation levels for these
genes were different for naive, unswitched and switched memory
B cells. For this reason, it is essential to analyse DNA methylation
using separate B-cell subsets, to distinguish between the change in
B-cell subset proportions and the existence of bona fide changes
in the DNA methylation status of these genes in specific B-cell
subpopulations.
Methylation impaired in naive-to-memory B cell transition.
To address the aforementioned question, we therefore proceeded
to analyse the DNA methylation levels in selected hypermethy-
lated genes for three B-cell subsets in a cohort of 12
healthy donors and 16 CVID patients. Specifically, we measured
the methylation levels of all these genes in naive (CD19þ
CD27 IgDþ ), unswitched (CD19þCD27þ IgDþ ) and
switched (CD19þCD27þ IgD ) memory B lymphocytes. The
relative numbers of these B-cell subsets differed between CVID
and healthy individuals. For an equivalent number of naive cells,
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Figure 1 | Comparison of B-cell DNA methylation profiles from MZ twins discordant for CVID. (a) Heatmap showing differentially methylated CpGs
between CD19þ B cells from twins discordant for CVID obtained from the DNA methylation array. A technical triplicate was analysed for each sample
(R1, R2 and R3). The heatmap scale shows the range of b-values, whereby positive (red) and negative (blue) values correspond, respectively, to a higher
and a lower methylation status than average. B cells from CVID twin showed 230 hypermethylated CpGs, while 81 CpGs were hypomethylated
(Db-valueZ0.1). (b) Genomic distribution of differentially methylated CpGs. The analysed CpGs could be associated with genes and localized in the 30
UTR, gene body or in the promoter region. At the promoter level, the CpGs could be localized within 1,500 bp of the transcription start site (TSS1500),
within 200 bp of the transcription start site (TSS200), in the 50 UTR or in the first exon. The CpGs that are not associated with genes are considered
intergenic. (c) Gene ontology enrichment analysis of genes associated with differentially methylated CpGs. The bar charts show the most relevant and
significantly enriched GO categories, the P values and the percentage of hypermethylated or hypomethylated genes in each category. (d) Heatmaps
showing the expression differences between a small cohort of CVID and healthy individuals for hypermethylated and hypomethylated genes (left and right
panels, respectively). The heatmap scale shows the range of expression values, whereby positive (red) and negative (blue) values correspond, respectively,
to a higher and a lower expression status than average. On the right of each heatmap, a Venn diagram shows the overlap between genes that are
hypermethylated and genes that are less strongly expressed in CVID with respect to healthy individuals or hypomethylated and genes that are expressed at
higher levels in CVID with respect to healthy individuals.
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the unswitched B-cell subset was present at similar levels in CVID
and healthy individuals; however, switched memory cells were
much less frequent in CVID individuals (Fig. 3a).
We then compared the methylation levels of the B-cell subsets
in the control group, observing a progressive loss of methylation
from naive cells to switched memory B cells (Fig. 3b and
Supplementary Data 2). For instance, BCL2L1 displayed an
average 79% methylation in naive cells, 49% in unswitched
memory cells and only 13% in switched memory cells (Table 2).
Similar changes towards lower DNA methylation levels from
naive-to-switched memory cells were found for all the other genes
in our list (Table 2), highlighting the close association between
the differentiation of naive cells to memory cells and the loss of
methylation in these relevant genes. DNA demethylation appears
to be independent of the global levels of enzymes involved in their
deposition (such as DNMT3a and DNMT3B) or removal (such as
TET2), as suggested by the absence of changes during naive-to-
memory B-cell differentiation (Fig. 3c).
Demethylation of these genes is compatible with the increased
expression levels of these genes and the function of their products
in memory cells. These results are also in agreement with the
progressive loss of methylation and gain of expression during
B-cell differentiation22. We used quantitative real-time PCR
(QRT–PCR) to measure mRNA levels of these genes, and
observed that normal individuals exhibit increasing levels of
genes such as BCL2L1, KCNC4 and CORO1B in the naive-to-
switched memory B-cell transition, confirming a relationship
between DNA demethylation and gain of expression (Fig. 4a).
In fact, analysis of histone modifications in the sequences
containing the CpG sites undergoing demethylation showed
an increase in the activating histone mark H3K4me3 during
naive to memory cell differentiation in genes such as BCL2L1
and PIK3CD (Fig. 4b), indicating a relationship between
DNA methylation, histone modifications and gene expression
and a less clear correlation for the repressive mark H3K27me3
(Fig. 4b).
Table 1 | Selected hypermethylated genes in B cells when comparing the CVID twin versus his healthy sibling.
Gene CpG number Localization DBeta
value
Relevance of gene products in B-cell context
BCL2L1 cg13989999 Body 0.13 The longest isoform encoded by this gene, BCL2-XL, is an apoptotic inhibitor and plays a critical
role in regulating cell survival in the GC. It has been reported that T lymphocytes from CVID
patients are more sensitive to apoptosis due to deregulation of this molecule.
TCF3 cg26615224 Body 0.13 Important transcription factor that mainly acts as gene activator. It is required for normal T- and
B-cell development.
PIK3CD cg03265564 50 UTR 0.11 The p110d catalytic subunit is mainly expressed in haematopoietic cells. This molecule mediates
the chemokine-induced migration, BCR signalling, BCR-induced proliferation and differentiation
into Antibody-producing cells
RPS6KB2 cg03559915 Body 0.15 This kinase is a downstream signalling protein of the mTOR pathway. S6K2 regulates cell growth
and protein synthesis
KCNN4 cg26890181 TSS1500 0.11 It is upregulated during B-cell activation and helps to maintain the enhanced cytosolic Caþ 2
levels during signal transduction
KCNC4 cg26189021 Body 0.14 This Kþ channel modulates the membrane potential directly by regulating the generation of




cg12044599 Body/TSS1500 0.17 Coronin 2, the protein product of the CORO1B gene, has been implicated in actin-based
processes such as cell migration. Coronin1A, another member of coronin protein familiy, has
been related to T-cell survival and has been associated with T-cell immunodeficiencies
cg23468927 Body/TSS1500 0.15 The protein encoded by PTPRCAP is required for normal antigen-receptor signalling and function
in lymphocytes. Its association with the protein phosphatase CD45 seems to modulate signal
transduction by regulating the CD45–LCK interaction
CCL5 cg10315334 50 UTR 0.13
XCL1 cg21872093 TSS1500 0.13 This chemokine is important in the regulation of T and B lymphocytes and neutrophil trafficking
WNT5A cg24049183 Body 0.17 WNT5A protects isolated GC B cells from apoptosis by initiating the noncanonical b-catenin-
independent signalling pathway
AKT3 cg24455383 Body 0.14 AKT, as the major effector downstream of PI3K signalling pathway, plays a key role in peripheral
B-cell maturation and survival
RPTOR cg00701918 Body 0.15 This component of the mTORC1 complex is one of the main targets of AKT. It is required for
proliferation of splenic B cells and promotes B-cell responses to LPS in the absence of PI3K
activation
IKBKE cg26859016 TSS1500 0.11 IKBKE is a noncanonical IKK family member that plays an important role in the regulation of
inflammatory signalling pathway. This kinase activates NF-kB and is able to activate AKT in a
PI3K-independent way.
STK11 cg08317252 Body 0.11 It has been reported that this master kinase is important for cessation of the GC reaction,
plasma cell differentiation and suppression of tumorigenesis
DUSP2 cg02431562 Body 0.13 This phosphatase is involved in the regulation of a number of MAP kinase-dependent
physiological processes occurring during the proliferation and differentiation of haematopoietic
cells
TNFRSF10A cg23303108 TSS1500 0.11 Receptor of the pro-apoptotic protein TRAIL, which has been involved in apoptosis, necessary to
eliminate primary plasma cells after the synthesis and secretion of large amounts of antibodies
HDAC4 cg11231069 Body 0.12 Chromatin modifier that is recruited by the transcriptional repressor BCL-6 to regulate
lymphocyte function, survival and differentiation
MTA3 cg06342490 TSS1500 0.15 MTA3 is a subunit of the transcriptional co-repressor Mi-2/NuRD, with a prominent role in
B-cell fate determination through its interaction with BCL-6
CVID, common variable immunodeficiency; GC, germinal centre; LPS, lipopolysaccharide; PI3K, phosphatidylinositol 3-kinase; TSS, transcription start site; UTR, untranslated region.
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Figure 2 | Validation of DNA methylation results by bisulfite pyrosequencing. (a) Schemes depicting a selection of genes indicating the differentially
methylated CpG site (red line) and its relative location with respect to the TSS (located with an arrow). Additional CpG sites are represented with vertical
black lines. CpG islands are represented with a green bar. (b) Bisulfite pyrosequencing of selected genes, all of which are relevant to B-cell biology. In
addition to CD19þ B lymphocytes, CD4þ T lymphocytes and CD14þ cells (monocytes) were analysed for all genes. Methylation levels are represented
as percentages. Bisulfite sequencing was technical triplicates of each sibling of the MWZ twin pair. Error bars correspond to s.d. Student’s t-test
comparisons with a P value above 0.05 are considered with a nonsignificant difference, and are not presented (c) b-values obtained from the DNA
methylation array. The B cells from CVID twin have higher levels of DNA methylation (DbZ0.1) in the analysed genes than those from his healthy sibling.
Black filled circles and black filled triangles, respectively, indicate the three b-values for the control twin and the CVID twin. The black line indicates the
average of the b-values in each condition.
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Figure 3 | Comparison of DNA methylation levels of selected genes in different B-cell subsets between CVID patients and healthy donors.
(a) Graph showing the relative number of cells in each B-cell subset (naive, unswitched (US) and switched (S) memory cells) in CVID patients and
healthy donors. The cell number is relative to the naive B-cell subset. Error bars correspond to s.e.m. (b) Box and whisker plots showing the percentage
of DNA methylation obtained by pyrosequencing in the eight validated genes. White boxes represent the DNA methylation levels in healthy donors.
Grey boxes represent DNA methylation levels in CVID patients. The analysed B-cell subsets were naive, unswitched and switched B cells. The P value is
shown for the cases with a statistically significant difference. The bottom and top of the box are the first and third quartiles, respectively, the band inside
the box is the median and the ends of the whiskers represent the minimum and maximum of all of the data. Student’s t-test comparisons with a P value
above 0.05 are considered with a nonsignificant difference, and are not presented. (c) Quantitative RT–PCR analysis comparing mRNA levels of DNMT3A,
DNMT3B and TET2 in different B-cell subsets in five CVID patients and four healthy controls. HPRT1 was used for normalization. In this analysis,
we compared five CVID patients and five controls. Error bars correspond to s.e.m.
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Most importantly, when we analysed the DNA methylation
levels of these genes in the three B-cell subsets in CVID patients,
we observed impairment in the loss of DNA methylation as cells
transition from naive to switched memory B cells (Fig. 3b). For
instance, focusing again on BCL2L1, the average methylation
levels were significantly higher for memory cells (both
unswitched and switched) in CVID individuals than in healthy
controls (Table 2). This behaviour was generally observed for all
genes (see Fig. 3b and Table 2). Analysis of variance (ANOVA)
test confirmed the generality of these findings across the panel of
genes analysed (see Supplementary Table 1). We observed that
the levels of methylation for all genes in naive B cells from CVID
individuals were almost identical to those from healthy controls.
However, the average levels for all these genes in unswitched and
switched B cells were higher for CVID than for control
individuals. In general, unswitched and switched memory B cells
tended to be hypermethylated relative to controls. This finding
suggests impaired loss of methylation for these genes during
B-cell differentiation in CVID patients. These differences in DNA
demethylation between CVID individuals and healthy controls
are not related to changes in the global levels in DNMTs or TET
proteins (Fig. 3c).
Regarding mRNA levels, we observed that CVID individuals
display altered levels in both unswitched and switched memory
cells, confirming the relevance of the observed impaired DNA
demethylation during differentiation to memory B cells (Fig. 4a).
For instance, BCL2L1, KCNC4 and CORO1B display lower levels
of expression in CVID individuals, supporting a functional
consequence of their impairment in DNA demethylation. In
addition, analysis of histone modifications H3K4me3 for some of
these sequences revealed lower levels in CVID individuals when
compared with healthy controls for genes such as BCL2L1 or
PIK3CD (Fig. 4b).
Discussion
Our study demonstrates for the first time the existence of DNA
methylation alterations in CVID, most notably, in genes relevant
to B-cell function. The observed changes in CVID individuals
indicate that the unswitched and switched memory cell subsets
are impaired to achieve the degree of DNA demethylation found
in healthy individuals. In contrast, the naive B-cell subset of
CVID patients displays normal levels of methylation. The
observed changes suggest a potential mechanism participating
in the defective generation of memory cells in CVID individuals.
In addition, our results prove that studies of MZ twins are
extremely valuable for identifying DNA methylation differences,
since interference with the genetic contribution is minimized and
it is possible to tease out the epigenetic component.
Various lines of evidence indicate that both genetic and
epigenetic factors play a role in the development of primary
immunodeficiencies30. Despite enormous efforts to elucidate the
genetic basis of CVID, its molecular basis remains elusive for
most patients. Several factors and pathways relevant to B-cell
biology have been associated with CVID in genetic studies. Our
analysis here has revealed additional elements of these pathways
that are altered at the DNA methylation level (Fig. 5). An
important target for alterations in CVID is the BCR signalling
pathway. BCRs initiate and control several key processes, such as
proliferation, differentiation, migration, activation and survival of
B cells, and signalling through this receptor is important not only
during the first steps of B-cell differentiation in the bone marrow,
but also for the proper function of fully differentiated B cells31.
Although the BCR has not been reported to be genetically altered
in CVID patients, and is by itself the source of a separate group of
PIDs, there is evidence of alterations in several molecules that are
necessary to its function in this disorder. For instance, genes that
encode molecules such as CD19, CD21, CD81 and CD2032–35 are
mutated in some CVID patients. CD19, CD21 and CD81 make
up the B-cell co-receptor complex, whose function is to decrease
the threshold of B-cell activation, conferring an enhanced
response against pathogens at low concentrations. Specifically,
CD81 is necessary for the expression of CD19, while CD21 is a
receptor for the complement component C3d. Moreover, CD19 is
responsible for BCR signal enhancement mainly through the
activation of PI3K signalling.
In our study, one of the most interesting genes displaying
increased DNA methylation in memory B cells from CVID
individuals was PIK3CD. This gene encodes p110d, the catalytic
subunit of one of the PI3K isoforms, a master regulator of B-cell
signalling due to its role in the transduction of signals from
different molecules and receptors. Through the generation of
inositol-1,4,5-trisphosphate 3 (PIP3), p110d recruits and activates
important proteins that drive the downstream effects of BCR
signalling26. Mutations in this gene have been described for
several PIDs10,36,37.
One of the downstream effects of PI3K signalling is the
increase in the intracellular Ca2þ levels to generate a ‘Ca2þ
signal’. PIP3 can induce the release of the calcium stores from the
endoplasmic reticulum to the cytosol. Another downstream effect
of PI3K signalling is the activation of the AKT/mTORC/SP6K
axis. PIP3 promotes the activation of AKT, which in
turn phosphorylates and activates the mTORC complexes.
Table 2 | DNA methylation levels in selected genes for CVID
and healthy cohorts in naive, unswitched and switched
memory B cells.
Gene Naı̈ve Unswitched Switched
AVG %Meth s.d. AVG %Meth s.d. AVG %Meth s.d.
BCL2L1
Control 79 22 49 25 13 6
CVID 80 31 62 25 21 24
TCF3
Control 87 7 42 20 21 10
CVID 77 29 62 32 32 25
PIK3CD
Control 80 23 33 18 18 16
CVID 82 23 54 29 31 26
RPS6KB2
Control 87 13 22 28 14 22
CVID 76 33 66 40 35 45
KCNN4
Control 93 8 35 28 8 9
CVID 86 15 53 37 11 9
KCNC4
Control 87 7 40 20 11 8
CVID 84 17 41 41 59 37
CORO1B/
PTPRCAP
Control 81 18 46 38 26 25
CVID 87 11 72 31 64 39
Control 81 31 21 29 18 23
CVID 88 15 44 40 31 38
Avg, average; CVID, common variable immunodeficiency; Meth, DNA methylation.
DNA methylation levels are measured by bisulfite pyrosequencing and represented as
percentage.
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The activated mTORC complexes then phosphorylate and
activate different substrates, such as the S6K2 kinase (encoded
by RPS6KB2; Fig. 5). We have also found this gene to be
hypermethylated in memory B cells in CVID patients. The S6K2
kinase has several substrates; however, its main function is to
phosphorylate the ribosomal protein S6, promoting cell growth
and protein synthesis.
Once the Ca2þ signal has been initiated, other proteins
become involved in the enhancement and maintenance of the
raised Ca2þ levels. Although Coronin 2, encoded by CORO1B,
also hypermethylated in CVID memory B cells, has not been
related to B cells directly, it has been reported that one member of
its family, CORO1A, has an important role in the immune system
through Ca2þ mobilization mediated by actin remodelling
changes. It is possible that CORO1B has similar roles in the
B-cell context, but this remains to be determined. Other
molecules with an important role in calcium signalling are
the potassium channels, like those encoded by other genes
hypermethylated in CVID B cells, KCNN4 and KCNC4 (Fig. 5).
They are responsible for maintaining the elevated calcium levels
through the mobilization of Kþ ions to the extracellular
medium.
B-cell differentiation and activation require high rates of
protein synthesis and proliferation. In normal conditions both
may provide an apoptotic stimulus, requiring the action of
anti-apoptotic molecules such as BCL2-XL (Fig. 5), encoded by
the BCL2L1 gene, and which are also hypermethylated in CVID
B cells. This protein maintains the mitochondrial potential
membrane and blocks the release of cytochrome c from
mitochondria.
Finally, at the end of BCR signalling there are the transcription
factors, which can transform the signals received at the cell
surface into gene expression changes that enable the cell to adapt
and respond. To ensure that the proper gene expression pattern is
achieved for the different stimuli, it is important not only for



















































































































































































































































Figure 4 | Comparison of the expression and histone modification levels of aforementioned selected genes in different B-cell subsets in healthy
donors and CVID patients. (a) Box and whisker plots showing quantitative RT–PCR analysis comparing mRNA levels of the selected genes in different
B-cell subsets in five CVID patients and four healthy controls. HPRT1 was used for normalization. Grey boxes represent expression levels in CVID patients.
The bottom and top of the box are the first and third quartiles, respectively, the band inside the box is the median and the ends of the whiskers represent
the minimum and maximum of all of the data. Student’s t-test comparisons with a P value above 0.05 are considered with a nonsignificant difference (n.s.).
(b) ChIP assays for two histone modifications, one activating marks (H3K4me3, blue bars) and one repressive mark (H3K27me3, red bars) focusing
on the same regions were changes in DNA methylation were identified. The values correspond to relative enrichment of the bound fraction with respect to
input. Negative control (immunoprecipitated with IgG) samples are also shown. The comparison corresponds to a technical triplicate of one CVID
individual and one healthy control. Error bars correspond to s.d.
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are not required to be blocked. E2A (encoded by another
hypermethylated gene in CVID memory B cells, namely TCF3;
Fig. 5) and NF-kB are two examples of transcription factors
activated during BCR signalling, while FOXO transcription
factors are blocked after BCR activation.
Our findings regarding the impaired ability to demethylate
genes during the transition from naive or memory cells reinforces
the notion emerging from various studies that CVID individuals
are deficient in differentiating towards memory B cells.
For instance, we have known for over 40 years that CD73
activity is reduced in B lymphocytes of patients suffering
from immunodeficiency syndromes38,39 and we now know that
CD73-dependent adenosine generation favours class-switch
recombination, endowing the B cell with an intrinsic control of
differentiation towards immunoglobulin class-switched plasma
cells40. As mentioned above, CVID patients have severely
deficient levels of switched memory B cells41. These altered
proportions of B-cell subsets are also reflected in the cell counts
in the cohort of CVID individuals analysed in this study.
Interestingly, at the DNA methylation level, genes such as
PIK3CD, RPS6KB2, KCNN4, KCNC4, CORO1B and BCL2L1 are
hypermethylated in memory B cells of CVID individuals relative
to healthy individuals, or, in other words, they do not undergo the
demethylation in the transition from naive to memory cells
observed in healthy individuals. This could also be interpreted as
meaning that if the DNA methylation patterns for these genes in
memory cells from CVID individuals were reminiscent of those
from naive cells, their ability to respond/maintain appropriate
responses could therefore be diminished.
Finally, our investigation demonstrates the utility of twin
studies for identifying epigenetic changes in complex diseases.
MZ twins share their entire genotype, including potentially
specific susceptibility gene variants. Therefore, our results
reinforce the notion that, for a particular genetic background,
DNA methylation changes are related to the onset of CVID.
However, we cannot distinguish whether these alterations in the
DNA methylation levels are a cause or a consequence; in other
words, whether the inability of certain CVID individuals to
demethylate these B-cell genes, perhaps influenced by the
environment, triggers the onset of CVID; or whether other
causes mark the development of CVID (for instance, in one twin



















































Figure 5 | Scheme depicting B-cell factors implicated in CVID, from genetic studies, or displaying DNA methylation alterations (from this study).
Molecules whose encoding genes have been reported to be altered in CVID are shown in blue. The products of genes that were found to be
hypermethylated in memory B cells in our study are shown in red. Molecules important in B-cell biology and related to the genetically or epigenetically
altered molecules are shown in grey. The table in the right bottom panel contains the names of the genes and proteins. The following proteins/genes are
also represented: BCR, B-cell receptor; Iga and Igb, BCR co-receptors; CD45, receptor-like tyrosine phosphatase, which regulates the action of the Src
family kinases. The bottom right table presents the names of the genes and proteins. The following molecules, proteins and organelles are depicted in dark
grey: P, phosphorylation; PIP2, phosphatidylinositol-4,5-biphosphate; PIP3, inositol-1,4,5-trisphosphate; PDK1, 3-phosphoinositide-dependent protein
kinase-1; p85, regulatory subunit of PI3K; S6, S6 ribosomal protein; Src, family of kinases, which triggers BCR signalling by phosphorylation of Iga and Igb;
ER, endoplasmic reticulum.
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methylation are an associated manifestation of CVID, which are
associated with deficient B-cell function.
A potential constraint on the use of this approach arises
from the fact that somatic mutations, for instance, in the
haematopoietic lineage, may arise during development and that
even MZ twins may not be not genetically identical in some
tissues. In addition, MZ monochorionic twins exchange blood
through shared vascular communication. Therefore, MZ twins
are a good model system for diseases, such as PIDs, that start to
develop after birth, when there is no blood sharing. Our data do
not allow us to draw any conclusions about the timing of the
DNA methylation changes observed, although it is likely that they
are associated with the onset of the disease.
A previous study by our team revealed the existence of DNA
methylation differences between MZ twins that are discordant for
SLE23, reinforcing the notion of an epigenetic component in
complex, immune-related diseases. Epigenetic differences in MZ
twins become more pronounced with age, supporting the idea
that ‘epigenetic drift’ plays a role in the divergence of MZ
phenotypes42. Another epigenetic study on MZ and DZ twins
provided further evidence that differences in epigenomes can
explain phenotypic differences43. The present report, in which the
discordance for CVID between a pair of MZ twins is used to
identify epigenetic targets, highlights the potential of this strategy
for learning about the contribution of epigenetics to immune-
related disorders as well as to other complex diseases.
Methods
Patients and ethics statement. Human blood samples used in this study were
obtained from CVID patients, diagnosed according to established criteria,
including one of the siblings of the MZ twin pair and from blood donors. They
were collected at the University Hospital Dr Negrı́n of Gran Canaria (MZ twins
discordant for CVID) and the University Hospital La Paz in Madrid (CVID cohort
and healthy donors). The blood donors received oral and written information
about the possibility that their blood would be used for research purposes, and any
questions that arose were then answered. Before giving their first blood sample
the donors signed a consent form approved by the Ethics Committee at their
corresponding hospital, which adhered to the principles set out in the WMA
Declaration of Helsinki. The protocol used to isolate B cells from these donors
was approved by IDIBELL’s Committee of Biosecurity (CBS) on 5 May 2011
and the Ethics Committee of the University Hospital of Bellvitge (CEIC) on
28 May 2011.
Sample preparation and isolation of B-cell subsets. Peripheral blood mono-
nuclear cells (PBMCs) from MZ twins were isolated by Lymphoprep (Stem Cell
Tech Inc., Vancouver, BC, Canada) density gradient centrifugation. The collected
cells were washed twice with ice-cold PBS, followed by centrifugation at
2,000 r.p.m. for 5 min. The CD19þ cells were isolated by positive selection using
CD19 MicroBeads (Miltenyi Biotec, Cologne, Bergisch Gladbach, Germany).
For the isolation of CVID and healthy control group B cells, PBMCs were
obtained from peripheral blood by Ficoll gradient using Lymphocyte Isolation
Solution (Rafer, Zaragoza, Spain). PBMCs were enriched in B cells by negative
depletion using CD3 and CD14 Microbeads (Miltenyi Biotec). For the isolation of
naive (CD19þCD27 IgDþ ), unswitched memory (CD19þCD27þ IgDþ )
and switched memory (CD19þCD27þ IgD ) B lymphocytes, B-cell-enriched
PBMCs were stained with CD19 fluorescein isothiocyanate, CD27 APC (Becton
Dickinson, Franklin Lakes, NJ, USA) and IgD PE (Southern Biotech, Birmingham,
AL, USA). Cells were sorted on a FACS Aria (Becton Dickinson). Purity check was
495% for all selected fractions. Purified samples were pelleted and stored at
 80 C.
DNA isolation and bisulfite modification. Pelleted cells were resuspended in
750ml of lysis buffer (50 mM Tris pH 8.8, 10 mM EDTA pH 8.3, 100 mM NaCl, 1%
SDS). In all, 50ml of proteinase K (10 mg ml 1) and 1 ml of glycogen (20 mg ml 1)
were added, and then incubated overnight at 37 C. After that time the degraded
proteins were precipitated by adding 340ml of 5 M NaCl and centrifuged at
maximum speed for 15 min. The supernatant was collected and 450 ml of 100%
isopropanol was added. The isolated DNA was then transferred to a new tube and
washed with 75% ethanol. The DNA was resuspended in 10 ml of DNAse-free
water. For the subsequent DNA methylation analysis the DNA samples were
bisulfite-converted using the EZ DNA methylation kit (Zymo Research, Orange,
CA, USA) following the manufacturer’s instructions.
DNA methylation profiling using universal bead arrays. The methylation
profiles of bisulfite-modified DNA of CD19þ cells from MZ twins discordant for
CVID were compared using the Infinium HumanMethylation450 BeadChips
(Illumina Inc., San Diego, CA, USA). This platform allows the interrogation of
4485,000 methylation sites per sample at single-nucleotide resolution, and com-
prises an average of 17 CpG sites per gene in the 99% of RefSeq genes. Ninety-six
percent of CpG islands are covered, with additional coverage in CpG island shores
and the regions flanking them. The samples were hybridized in the array following
the manufacturer’s instructions. Each methylation data point is obtained from a
combination of the Cy3 and Cy5 fluorescent intensities from the M (methylated)
and U (unmethylated) alleles. Background intensity computed from a set of
negative controls was subtracted from each data point. For further analysis we used
the b value of each CpG, which is the ratio of the methylated probe intensity to the
overall intensity (sum of methylated and unmethylated probe intensities).
The value of b ranges from 0 (non-methylation) to 1 (total methylation).
Selection of differentially methylated CpG candidates. We estimated the
b values following what was defined as the optimal three-step pipeline in ref. 44.
For the differential methylation we transformed b values into M values
(as suggested in ref. 45) and used limma Bioconductor package for the differential
methylation analysis. Given that (1) technical variability was similar to biological
variability, (2) many DNA methylation changes were expected to be mild and
(3) the reduced number of samples (one twin pair), we made a conservative
selection of probes as candidate differentially methylated sites: (i) 10% or greater
difference in the b-value DNA methylation between MZ twins, (ii) P value smaller
than 0.01 and (iii) in the three replicates the b-value estimated of one twin was
always larger or always smaller than that of the other twin. The P value obtained in
(ii) computes the difference of methylation between twins by using the three
technical replicates per individual; we only made use of this contrast as a selection
criterion that allows the identification of CpG sites where the difference in
methylation is larger than the technical variation. This selection criterion returned
a selection of 311 differentially methylated candidate sites. Those sites are not
statistically significant if FDR or FWER is considered; however, they provide a
robust initial candidate selection.
Gene ontology analysis. The Gene Symbol of probes differentially methylated
were uploaded in the AmiGO database46. We performed GO enrichment analysis
focusing on Biological Process categories on the basis of genes that displayed
at least twofold differential methylation compared with each probe. To filter
non-enrichment GO terms we applied a threshold P value and adjusted P value of
less than 0.05. The hypermethylated and hypomethylated genes were also analysed
with Ingenuity programme and GO database. The hypermethylated genes were
selected on the basis of their constant presence in relevant B-cell signalling
pathways, their implication in common regulatory networks and functions related
to BCR signalling.
Gene expression data analysis. We compared the expression array values
from GSE17269 Affymetrix Human Genome U133 Plus 2.0 Array microarray29.
Specifically, we compared expression data of B cells from CVID donors and healthy
donors. To obtain differential expression values between diseases and control
samples, we used Bioconductor package Affy functions to read Affymetrix samples
with CEL format. The Limma package was then used to estimate the differential
expression of each probe ID, using the same parameters as estimated in the original
study. Raw differential expression data were selected on the basis of them showing
a lower than 0.5-fold or greater than 1.5-fold change and a P value less than 0.05.
Finally, the overlap of differentially methylated and differentially expressed gene
values was evaluated using Gene Symbol as ID and the n-fold change as numeric
values.
To test the expression of selected genes, we isolated RNA from naive,
unswitched and switched memory cells using the RNeasy Plus Micro Kit (Qiagen,
Venlo, Limburg, the Netherlands) adding MS2 RNA (Roche, Basel, Switzerland) to
stabilize the RNA template. We reverse-transcribed total RNA using Transcriptor
First Strand cDNA Synthesis Kit from Roche Diagnostics. QRT–PCR analysis was
performed in a PCR Real-Time LightCycler 480 (Roche) with SYBR green. Primer
sequences are listed in Supplementary Table 2.
Bisulfite pyrosequencing. To validate the results from the DNA methylation
array, we selected seven differentially methylated CVID-relevant genes with which
to perform the pyrosequencing analysis. We analysed the samples of CD19þ cells
from MZ twins and a panel of 84 samples corresponding to three different cell
populations: naı̈ve, unswitched and switched B cells, of a panel of CVID patients
and healthy donors. Biotinylated amplicons for each gene were generated with PCR
using the HotStart Taq DNA polymerase PCR kit (Qiagen). Specific primers were
designed using the PyroMark Assay Design Software (QIAGEN version 2.0.01.15).
Pyrosequencing reactions were performed and DNA methylation quantified with
the Pyromark Q24 system (Qiagen). Results from bisulfite pyrosequencing are
presented as the percentage of methylation. Raw bisulfite sequence data are
provided as Supplementary Data 2. Primer sequences are listed in Supplementary
Table 2.
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Chromatin immunoprecipitation assays. Chromatin immunoprecipitation
(ChIP) assays were performed using LowCell# ChIP kits (Diagenode, Seraing,
Belgium) following the manufacturer’s instructions on naive, unswitched and
switched memory cells crosslinked with 1% formaldehyde for 10 min. We used the
following antibodies: H3K4me3 (no. CS200580, Millipore, Billerica, MA, USA) and
H3K27me3 (ref: 07–449, Millipore). Primer sequences are listed in Supplementary
Table 2.
Statistical analysis. The B-cell subsets from CVID patients and healthy donors
were compared using a Student’s t-test and ANOVA. P values less than 0.05 were
considered statistically significant.
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